Zydus to Pay $120 Million to Settle US Patent Dispute with Astellas Over Mirabegron

Zydus Lifesciences and its US subsidiary have agreed to pay $120 million to Astellas Pharma to resolve a patent dispute related to the bladder disorder drug Mirabegron.

As part of the agreement, Zydus will also pay a prepaid per-unit licensing fee on US sales of its generic version of the drug from the date of the settlement until September 2027. Other terms of the deal remain confidential.

Impact on US Market Presence

The settlement allows Zydus to continue marketing generic Mirabegron in the United States, ensuring uninterrupted participation in the market.

This development follows a similar move by Lupin, which recently settled its dispute with Astellas for $90 million over the same drug.

About Zydus Lifesciences

Zydus Lifesciences Limited, earlier called Cadila Healthcare Limited, is an Indian multinational pharmaceutical company based in Ahmedabad. The company mainly focuses on producing generic medicines and was ranked 100th in the Fortune India 500 list in 2020.

Zydus Lifesciences Share Price Movement

Zydus Lifesciences share price (NSE: ZYDUSLIFE) share price was trading at ₹919.10, up ₹20.80 (2.32%) as of 10:10 am IST on February 12. The stock opened at ₹900.30, touched a high of ₹922.40, and a low of ₹896.05 during the session. Over the past year, the stock has recorded a 52-week high of ₹1,059.05 and a 52-week low of ₹795.00, while offering a dividend yield of 1.20% with a quarterly dividend amount of ₹2.76.

Read More: Best Gold Stocks in India for February 2026: Titan, Thangamayil and More Based on 5-Yr CAGR!

Conclusion

Zydus’ settlement with Astellas removes legal uncertainty and secures continued access to the US Mirabegron market, while the possibility of delayed competition could provide short-term commercial advantages.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.